

Breast Cancer

| | Endocrine Therapy | ER/PR-POSITIVE HER2 NEGATIVE | HER2 POSITIVE | "TRIPLE NEGATIVE" EP/PR -NEGATIVE HER2-NEGATIVE |
|-------------------------------|---|--|--|--|
| Pre-Op Therapy | No Trial Currently Available | IRB#6256 -ISPY2 Investigation of Serial Studies to Predict your Therapeutic response with imaging/molecular | | |
| Surgical Therapy | IRB#9340 - Phase II breast conservation surgery and radiation therapy study | | | |
| Adjuvant Therapy | IRB 17504 MonarchE | | IRB#15366 Phase 2 Study of ONT-380 vs. Placebo with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (Applies to Adjuvant, 1 st line and beyond HER2 + MBC therapy) | IRB# 17461 S1418 A Randomized, Phase III Trial to Evaluate the Efficacy and |
| 1st line MBC Therapy | No Trial Currently Available | IRB#11351 Phase 3 Trial of Standard Chemotherapy With or Without a PARP Inhibitor in Metastatic or Locally Advanced Unresectable Breast | IRB # 17016 COMPLEEMENT-1: An open -label Phase 3 to evaluate safety and efficacy of ribociclib in compination with letrozole | IRB#11351 Phase 3 Trial of Standard Chemotherapy With or Without a PARP Inhibitor in Metastatic or IRB#17267 Phase 2 Cobimetinib + Atezolizumab + nab- |
| 2nd line MBC Therapy | No Trial Currently Available | IRB#16379 C31006: An Open-Label Phase 2 Study of MLN0128 (A TORC1/2 Inhibitor) in Combination With Fulvestrant in Women With ER-Positive/HER2-Negative Advanced or Metastatic Breast Cancer That Has | No Trial Currently Available | No Trial Currently Available |
| 3rd line MBC Therapy | IRB # 15588 SMMART | | | |
| "Heavily Pre-treated" Therapy | No Trial Currently Available | No Trial Currently Available | No Trial Currently Available | IRB # 17887 |

Key

| | |
|--|---------------------|
| | Open for Enrollment |
| | In Development |
| | Enrollment on Hold |